Hudson Edge Investment Partners’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.42M Sell
138,879
-29,888
-18% -$1.74M 1.23% 12
2025
Q4
$9.1M Buy
168,767
+23,799
+16% +$1.14M 1.35% 9
2025
Q3
$6.54M Buy
144,968
+13,394
+10% +$626K 1.06% 41
2025
Q2
$6.09M Buy
131,574
+17,191
+15% +$844K 1.04% 40
2025
Q1
$6.98M Sell
114,383
-13,804
-11% -$805K 1.42% 10
2024
Q4
$7.25M Sell
128,187
-9,511
-7% -$531K 1.34% 10
2024
Q3
$7.12M Buy
137,698
+6,676
+5% +$313K 1.32% 8
2024
Q2
$5.44M Buy
131,022
+6,757
+5% +$302K 1.05% 36
2024
Q1
$6.74M Buy
124,265
+8,469
+7% +$431K 1.32% 12
2023
Q4
$5.94M Buy
115,796
+15,983
+16% +$839K 1.38% 18
2023
Q3
$5.79M Buy
99,813
+8,229
+9% +$504K 1.89% 10
2023
Q2
$5.86M Buy
91,584
+3,322
+4% +$223K 1.86% 17
2023
Q1
$6.12M Buy
88,262
+15,120
+21% +$1.07M 1.9% 8
2022
Q4
$5.26M Buy
73,142
+340
+0.5% +$25.6K 1.8% 7
2022
Q3
$5.17M Sell
72,802
-7,674
-10% -$557K 1.93% 7
2022
Q2
$6.2M Sell
80,476
-11,447
-12% -$872K 2.26% 3
2022
Q1
$6.71M Sell
91,923
-13,245
-13% -$889K 2.11% 5
2021
Q4
$6.56M Buy
105,168
+11,714
+13% +$687K 2.03% 4
2021
Q3
$5.53M Buy
93,454
+6,464
+7% +$426K 1.82% 6
2021
Q2
$5.81M Buy
86,990
+4,192
+5% +$273K 1.85% 5
2021
Q1
$5.23M Buy
82,798
+5,275
+7% +$328K 1.73% 12
2020
Q4
$4.81M Buy
77,523
+5,642
+8% +$347K 1.71% 14
2020
Q3
$4.33M Sell
71,881
-26,353
-27% -$1.59M 1.74% 8
2020
Q2
$5.78M Sell
98,234
-24,875
-20% -$1.49M 1.86% 12
2020
Q1
$6.86M Sell
123,109
-1,449
-1% -$88.6K 2.61% 2
2019
Q4
$8M Sell
124,558
-21,951
-15% -$1.26M 2.1% 3
2019
Q3
$7.43M Sell
146,509
-500
-0.3% -$23.5K 2.09% 5
2019
Q2
$6.67M Buy
147,009
+8,058
+6% +$375K 1.94% 10
2019
Q1
$6.63M Sell
138,951
-7,641
-5% -$381K 2% 13
2018
Q4
$7.62M Sell
146,592
-61,840
-30% -$3.32M 2.36% 3
2018
Q3
$12.9M Sell
208,432
-16,579
-7% -$984K 2.3% 4
2018
Q2
$12.5M Buy
225,011
+148
+0.1% +$7.99K 2.32% 3
2018
Q1
$14.2M Sell
224,863
-33,054
-13% -$2.13M 2.15% 10
2017
Q4
$15.8M Sell
257,917
-7,324
-3% -$458K 2.18% 8
2017
Q3
$16.9M Sell
265,241
-54,074
-17% -$3.16M 2.4% 2
2017
Q2
$17.8M Buy
319,315
+10,490
+3% +$571K 2.5% 6
2017
Q1
$16.8M Buy
308,825
+53,221
+21% +$2.92M 2.24% 7
2016
Q4
$14.9M Buy
255,604
+27,444
+12% +$1.5M 2.04% 19
2016
Q3
$12.3M Buy
228,160
+215,865
+1,756% +$13.9M 1.84% 29
2016
Q2
$904K Sell
12,295
-105
-0.8% -$7.42K 0.13% 56
2016
Q1
$792K Sell
12,400
-100
-0.8% -$6.31K 0.08% 107
2015
Q4
$860K Hold
12,500
0.08% 104
2015
Q3
$740K Buy
12,500
+700
+6% +$44.4K 0.04% 106
2015
Q2
$785K Sell
11,800
-1,060
-8% -$69.9K 0.03% 107
2015
Q1
$829K Sell
12,860
-200
-2% -$12.5K 0.03% 107
2014
Q4
$771K Hold
13,060
0.03% 105
2014
Q3
$668K Hold
13,060
0.02% 105
2014
Q2
$634K Buy
13,060
+10
+0.1% +$493 0.02% 105
2014
Q1
$678K Hold
13,050
0.03% 103
2013
Q4
$694K Sell
13,050
-150
-1% -$7.64K 0.03% 103
2013
Q3
$611K Sell
13,200
-250
-2% -$11K 0.03% 103
2013
Q2
$601K Buy
+13,450
New +$584K 0.02% 105

Other funds holding BMY

Hudson Edge Investment Partners's BMY Position: Q1 2026 in Review

Hudson Edge Investment Partners reduced its Bristol-Myers Squibb (BMY) stake by 18% in Q1 2026, selling an estimated $1.74M and leaving 138,879 shares worth $8.42M. The position accounts for 1.23% of the portfolio, ranked #12.

Hudson Edge Investment Partners first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $17.8M in Q2 2017. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Hudson Edge Investment Partners held 138,879 shares of Bristol-Myers Squibb worth $8.42M as of Q1 2026.
  • Hudson Edge Investment Partners sold 29,888 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.74M.
  • Bristol-Myers Squibb made up 1.23% of Hudson Edge Investment Partners's portfolio in Q1 2026, its #12 holding.
  • Hudson Edge Investment Partners first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Hudson Edge Investment Partners's Bristol-Myers Squibb position peaked at $17.8M in Q2 2017.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Hudson Edge Investment Partners's 13F filing for Q1 2026, filed 27 Apr 2026.